BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: CREB binding protein (CREBBP; CBP); E1A binding protein p300 (EP300; p300); interleukin-17A (IL-17A)

September 17, 2015 7:00 AM UTC

Patient sample studies suggest inhibiting CREBBP and EP300 could help treat ankylosing spondylitis, psoriatic arthritis and other autoimmune diseases involving IL-17A-mediated inflammation. In culture...